Loading
companiesCompany
Sandoz
Sandoz, spun out of Novartis in 2023, is the world's largest generics and biosimilars company; in oncology it sells biosimilar filgrastim (Zarxio), pegfilgrastim (Ziextenzo) and rituximab, and holds the US application for nelarabine (Arranon).
Overview
Sandoz, based in Basel and listed as SDZ.SW, was spun out of Novartis in 2023 and is the world's largest generics and biosimilars company; in oncology it sells biosimilar filgrastim as Zarxio, pegfilgrastim as Ziextenzo and rituximab, and holds the US application for nelarabine, sold as Arranon. It launched the first US biosimilar, Zarxio or filgrastim-sndz, in 2015, markets biosimilars of pegfilgrastim, rituximab, trastuzumab and denosumab in Europe and the United States, and carries a broad line of generic oncology injectables. OnCo links it to filgrastim, pegfilgrastim and nelarabine. Whether biosimilar competition lowers the cost of supportive care and antibody therapy as much as small-molecule generics did is the open question its portfolio tests. Each product has its own page.
Headquarters
Basel, CH
Scorecard
All companies#85of 1244 companies, score 54
- approved products +18
- modalities +4
- regions +2
- registry trials +30
3 approved, 0 in phase 3, 0 earlier, 0 targets, 1,532 registry studies. Formula on the scorecards page.
Type
Large pharma · SDZ.SW
Stage
Public
Website
ApprovedRecombinant granulocyte colony-stimulating factor
Filgrastim (G-CSF) · Neupogen
Filgrastim (Neupogen and its biosimilars) is a daily injection that speeds the recovery of infection-fighting white cells after chemotherapy, lets doctors give chemotherapy on schedule and mobilises stem cells for transplant.
ApprovedPurine nucleoside prodrug (antimetabolite)
Nelarabine · Arranon
Nelarabine (Arranon) is an infusion for T-cell acute lymphoblastic leukaemia and lymphoma that has come back after at least two other treatments; it is now also added to first-line therapy for children with T-cell leukaemia.
ApprovedPegylated recombinant granulocyte colony-stimulating factor
Pegfilgrastim · Neulasta
Pegfilgrastim (Neulasta) is a long-acting form of the growth factor G-CSF, given once per chemotherapy cycle to speed white cell recovery and prevent febrile neutropenia; one dose replaces about eleven daily filgrastim injections. Biosimilars have been sold since 2018 and the Onpro on-body injector delivers it automatically the day after chemotherapy; bone pain is the main side effect.
Similar pages
- CompanyViatris
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Pegfilgrastim, Generic sterile injectables (the 2023 platinum shortage).
- CompanyAmneal Pharmaceuticals
Shares Oral solid dose manufacturing (tablets and capsules), Generic sterile injectables (the 2023 platinum shortage).
- TrialTrial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
Shares Pegfilgrastim, Filgrastim (G-CSF).
- CompanyIntas Pharmaceuticals (Accord Healthcare)
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Generic sterile injectables (the 2023 platinum shortage).
- CompanyEurofarma
Shares Biosimilar manufacturing and comparability, Pegfilgrastim, Filgrastim (G-CSF).
- CompanyDr. Reddy's Laboratories
Shares Oral solid dose manufacturing (tablets and capsules), Biosimilar manufacturing and comparability, Generic sterile injectables (the 2023 platinum shortage).
- CompanyTeva Pharmaceuticals
Shares Oral solid dose manufacturing (tablets and capsules), Filgrastim (G-CSF), Generic sterile injectables (the 2023 platinum shortage).
- TargetG-CSF receptor (CSF3R)
Shares Pegfilgrastim, Filgrastim (G-CSF).
technologies
drugs
ApprovedRecombinant granulocyte colony-stimulating factor
Filgrastim (G-CSF) · Neupogen
ApprovedPurine nucleoside prodrug (antimetabolite)
Nelarabine · Arranon
ApprovedPegylated recombinant granulocyte colony-stimulating factor
Pegfilgrastim · Neulasta